According to recent research summarized in a Reuters report, an experimental antibody developed by Merck & Co. reduced the recurrence of Clostridium difficile infections by 10 percentage points. In ...

Charles Darkoh, Ph.D., a researcher at The University of Texas Health Science Center at Houston (UTHealth) School of Public Health, was recently awarded a five-year, $1.9 million R01 grant by the ...

Clostridium difficile bacteria, computer illustration. C. difficile is a normal inhabitant of the human intestine, but it can become a pathogen when antibiotics disrupt the normal intestinal flora and ...

A novel vaccination approach developed by Vanderbilt Health researchers cleared the harmful gut bacterium Clostridioides difficile (C. diff) in an animal model of infection. An experimental vaccine ...

Iron storage “spheres” inside the bacterium C. diff — the leading cause of hospital-acquired infections — could offer new targets for antibacterial drugs to combat the pathogen. A team of Vanderbilt ...

Nearly half a million people in the United States suffer from an intestinal infection called Clostridium difficile each year. Approximately half of those individuals become sick enough to require ...

Matthew Munneke, left, and Eric Skaar, PhD, MPH, use anaerobic chambers to study bacteria like C. diff that die in the presence of oxygen. The pathogen C. diff — the most common cause of health ...

The pathogen C. diff - the most common cause of health care-associated infectious diarrhea - can use a compound that kills the human gut's resident microbes to survive and grow, giving it a ...

Newly discovered iron storage 'ferrosomes' inside the bacterium C. diff -- the leading cause of hospital-acquired infections -- are important for infection in an animal model and could offer new ...

The pathogen C. diff -- the most common cause of health care-associated infectious diarrhea -- can use a compound that kills the human gut's resident microbes to survive and grow, giving it a ...